DDInter1593 DDInter899
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Rifaximin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifaximin {u} (Compound) binds {v} (Gene) NR1I2
Rifaximin {u} (Compound) upregulates {v} (Gene) GPX3
Rifaximin {u} (Compound) is included by {v} (Pharmacologic Class) Rifamycins
Rifaximin {u} (Compound) causes {v} (Side Effect) Memory impairment
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Rifaximin (Compound) resembles Rifampicin (Compound)
Rifaximin (Compound) binds NR1I2 (Gene)
Rifaximin (Compound) upregulates GPX3 (Gene)
Rifaximin (Compound) is included by Rifamycins (Pharmacologic Class)
Rifaximin (Compound) causes Memory impairment (Side Effect)
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib